A brain tumour is an abnormal mass of tissue. Brain tumours vary in size, from tiny to large. Moreover, they display variations in location, shape, and size, which add complexity to their detection. The accurate delineation of tumour regions poses a challenge due to their irregular boundaries. In this research, these issues are overcome by introducing the DTDO-ZFNet for detection of brain tumour. The input Magnetic Resonance Imaging (MRI) image is fed to the pre-processing stage. Tumour areas are segmented by utilizing SegNet in which the factors of SegNet are biased using DTDO. The image augmentation is carried out using eminent techniques, such as geometric transformation and colour space transformation. Here, features such as GIST descriptor, PCA-NGIST, statistical feature and Haralick features, SLBT feature, and CNN features are extricated. Finally, the categorization of the tumour is accomplished based on ZFNet, which is trained by utilizing DTDO. The devised DTDO is a consolidation of DTBO and CDDO. The comparison of proposed DTDO-ZFNet with the existing methods, which results in highest accuracy of 0.944, a positive predictive value (PPV) of 0.936, a true positive rate (TPR) of 0.939, a negative predictive value (NPV) of 0.937, and a minimal false-negative rate (FNR) of 0.061%.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1080/0954898X.2024.2351159 | DOI Listing |
Pharmacol Res
January 2025
Department of Physiology, Tongji Medical College of Huazhong University of Science & Technology, Wuhan, 430030, PR China. Electronic address:
Pediatric high-grade gliomas (pHGGs) are the most common brain malignancies in children and are characterized by blocked differentiation. The epigenetic landscape of pHGGs, particularly the H3K27-altered and H3G34-mutant subtypes, suggests these tumors may be particularly susceptible to strategies that target blocked differentiation. Differentiation therapy aims to overcome this differentiation blockade by promoting glioma cell differentiation into more mature and less malignant cells.
View Article and Find Full Text PDFCurr Med Chem
January 2025
Shree S. K. Patel College of Pharmaceutical Education and Research, Ganpat University, Kherva, 384012, India.
Aims: This study aimed to develop Imatinib Mesylate (IMT)-loaded Poly Lactic-co-Glycolic Acid (PLGA)-D-α-tocopheryl polyethylene glycol succinate (TPGS)- Polyethylene glycol (PEG) hybrid nanoparticles (CSLHNPs) with optimized physicochemical properties for targeted delivery to glioblastoma multiforme.
Background: Glioblastoma multiforme (GBM) is the most destructive type of brain tumor with several complications. Currently, most treatments for drug delivery for this disease face challenges due to the poor blood-brain barrier (BBB) and lack of site-specific delivery.
Transl Cancer Res
December 2024
BGI Research, Chongqing, China.
Background: Medulloblastoma (MB) is a highly malignant childhood brain tumor. Previous research on the genetic underpinnings of MB subtypes has predominantly focused on European and American cohorts. Given the notable genetic differences between Asian and other populations, a subtype-specific study on an Asian cohort is essential to provide comprehensive insights into MB within this demographic.
View Article and Find Full Text PDFTransl Cancer Res
December 2024
Department of Radiation Oncology, The Second Hospital of Lanzhou University, Lanzhou, China.
Background: Within the realm of primary brain tumors, specifically glioblastoma (GBM), presents a notable obstacle due to their unfavorable prognosis and differing median survival rates contingent upon tumor grade and subtype. Despite a plethora of research connecting cardiotrophin-1 (CTF1) modifications to a range of illnesses, its correlation with glioma remains uncertain. This study investigated the clinical value of CTF1 in glioma and its potential as a biomarker of the disease.
View Article and Find Full Text PDFHeliyon
January 2025
Children's Brain Tumour Research Centre, School of Medicine, Biodiscovery Institute, University of Nottingham, UK.
Isocitrate dehydrogenase wild-type glioblastoma (GBM) is characterised by a heterogeneous genetic landscape resulting from dynamic competition between tumour subclones to survive selective pressures. Improvements in metabolite identification and metabolome coverage have led to increased interest in clinically relevant applications of metabolomics. Here, we use liquid chromatography-mass spectrometry and gene expression microarray to profile integrated intratumour metabolic heterogeneity, as a direct functional readout of adaptive responses of subclones to the tumour microenvironment.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!